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Abstract 
Application of traditional somatic evolutionary theory can offer an appropriate context for studying tumor growth 
at the molecular level. However, high degrees of heterogeneity (especially genome-level heterogeneity) within 
tumors coupled with a lack of common driver mutations have posed a challenge to the generally accepted stepwise 
concept of cancer evolution, where clonal expansion is the key. In order to account for multiple levels of 
heterogeneity and better understand tumor growth and progression, a new, holistic conceptual framework must be 
applied in cancer research. Herein, we discuss one such framework, the genome theory of cancer evolution, with 
respect to tumor growth. This includes detailing the ultimate importance of chromosome aberrations in cancer, the 
somatic cell evolutionary pattern, and single-cell/population growth dynamics. Under this new framework, tumor 
growth is a highly dynamic process where emergent outlier subpopulations can greatly influence the pattern of 
progression and the direction of evolution. Further, genome level changes have a greater impact on cancer 
evolution than individual gene mutations in most cancer types, as karyotype alteration often results in altered 
system inheritance which defines the network structure and even can change the meaning of individual genes 
(representing 'parts inheritance' by changing the gene context. Based on this analysis, we call for a focus shift back 
on cytogenetic and cytogenomic alterations (especially on non-clonal chromosomal aberrations) in monitoring 
population growth, identifying the emergence of new subpopulations and studying patterns of evolutionary 
dynamics. This new insight has implications in understanding cancer evolution in general as well as searching for 
new diagnostic and treatment strategies. 
Introduction 
Cancer progression represents an evolutionary 
process (Gatenby et al., 2009; Greaves and Maley, 
2012; Heng et al., 2006a; Merlo et al., 2006; Nowell, 
1976). There are heritable variations (genetic, 
epigenetic, genomic), and the variants display 
different levels of fitness, which are essential for 
tumor populations to adapt and grow. While 
accepted, detailed mechanisms of how somatic cell 
evolution works are not well understood. These 
include the relationship between tumor evolution 
and tumor growth, the emergence of dominant cell 
populations, and the dynamics of tumor populations 
under high levels of stress, such as chemotherapy.  
To elucidate these mechanisms, efforts are needed to 
re-examine various types of heritable variations and 
how these variations contribute to cancer evolution. 
The study of classical molecular evolution focuses 
largely on gradual gene-level change over time. 
Cancer evolution research has followed the same 
paradigm, reasoning that individual genetic or 
epigenetic alterations and the molecular pathways 
they participate in result in increased fitness, driving 
the growth of cancer. According to gene mutation 
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theory, cancer is the result of a stepwise 
accumulation of small changes in commonly shared 
genes, so the logical approach is to look for specific 
gene mutations that drive cancer evolution. Thus, in 
order to study tumor growth at the genetic level, 
identification of common genetic aberrations (e.g. 
universal chromosomes or shared key gene 
mutations) is key, which in turn would serve as 
potential diagnostic and therapeutic targets to 
eradicate cancer. 
Unfortunately, this approach has been proven less 
successful to explain most cancers, aside from 
exceptional cases including chronic phase chronic 
myeloid leukemia (Horne et al., 2013a). Further, 
increased efforts to identify common drivers have 
resulted in massive amounts of varying and 
conflicting data. Most solid tumors are marked by 
high degrees of intra- and inter-tumor genome 
heterogeneity at multiple genetic and non-genetic 
levels, and this was recently confirmed with high-
throughput sequencing (Gerlinger et al., 2012; Heng 
et al., 2009; Heppner, 1984). The high degrees of 
heterogeneity characteristic of tumors coupled with 
a lack of shared driver mutations have posed a 
challenge to the stepwise concept of cancer 
evolution (Heng, 2007a; Heng et al., 2013a; Podlaha 
et al., 2012). More troubling, this has resulted in 
confusion in the field, as these results would suggest 
that individual genes and pathways offer only a 
minimal contribution to the general cancer patient 
population and thus hold limited clinical value. 
One of the major contributions of cancer genome 
sequencing is the confirmation of previous 
cytogenetic findings, which have shown that genome 
level alteration is key for most cancers. Cytogenetic 
studies and genome sequencing efforts have revealed 
high rates of chromosomal abnormalities in clinical 
samples. Subsets of genome chaos (rapid, stochastic 
chromosome fragmentation and reorganization) 
including chromothripsis and chromoplexy have 
been detected in various types of cancer, and chaotic 
genomes have been displayed in the majority of 
cases of certain cancer types (Baca et al., 2013; Heng 
et al., 2011a; Heng et al., 2011b; Liu et al., 2014; 
Stephens et al., 2011). These chromosomal 
aberrations are necessary for the progression of 
cancer as they provide tumor populations 
heterogeneity and thus immense evolutionary 
potential. Chromosomal alterations can drastically 
impact cells at the genetic and phenotypic levels, 
including altering a cell's transcriptome and 
proliferation rate (Abdallah et al., 2013; Kreso et al., 
2013; Stevens et al., 2014). Changes of this 
magnitude explain the relative paltry impact that 
individual genes and pathways seem to have in the 
face of genome alteration mediated macro-evolution. 
Changes in chromosomal topology can have far 
greater effects on tumor phenotype than changing 
individual pathways by gene mutation. That is the 
reason why there are so many different types of non-
clonal chromosomal aberrations (NCCAs) detected 
in various cancers and other diseases (Gisselsson and 
Hoglund, 2005; Heng et al., 2004; Heng et al., 
2013b; Horne et al., 2014a). 
To make sense of this heterogeneity and better 
understand tumor growth and cancer progression, a 
new conceptual framework must be applied in 
cancer research that accounts for and unifies the 
molecular diversity of the disease (Heng et al., 
2010a; Horne et al., 2014b; Ye et al., 2009). One 
such framework is the genome theory of cancer 
evolution (Heng et al., 2006a; Heng et al., 2006b; 
Heng, 2009). Herein, we discuss genome-mediated 
cancer evolution as it pertains to tumor growth. 
Specifically, we underscore the importance of 
chromosome aberrations in cancer, review the 
somatic cell evolutionary pattern and describe single 
cell and population growth dynamics in this context. 
Interestingly, under this holistic framework, tumor 
growth is a highly dynamic process where emergent 
outlier subpopulations can greatly influence further 
progression. These new findings are essential to 
understanding the process of tumor evolution, as 
growth patterns, drivers, and overall tumor 
progression rely on multiple levels of heterogeneity. 
Finally, we call for a re-emphasis on cytogenetic and 
cytogenomic alterations in monitoring population 
growth, identifying the emergence of new 
subpopulations and studying patterns of 
evolutionary dynamics. In most cancer types, 
especially solid tumors, genome level changes have 
a greater impact on cancer evolution compared to 
individual gene mutations, especially during the 
punctuated phase where macro-cellular evolution 
dominates, which differs from the diversification 
phase (Horne et al., 2014b). This new insight has 
implications in cancer treatment strategies, as the 
key to improving patient outcome may lie in tumor 
constraint rather than aiming to maximize tumor cell 
death. 
Genome theory emphasizes the 
ultimate importance of 
chromosome aberrations in 
cancer 
At the center of this new framework is the 
redefinition of the genome, the highest level of 
genetic organization. More than the complete 
genetic sequence, the three-dimensional genome 
topology defines and governs the overall genetic 
network. The genome also acts as the main selection 
platform in evolution. This is evidenced by the 
constraint applied to genome integrity during sexual 
reproduction, resulting in the preservation of the 
karyotype or species identity (Gorelick and Heng, 
2011; Heng, 2007b; Horne et al., 2013b; Wilkins and 
Holliday, 2009). This high level of constraint does 
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not apply to asexual somatic cell evolution, allowing 
for rapid cellular evolution to occur through various 
chromosomal aberrations within individuals. 
Under the genome theory, new karyotypes define 
new system inheritance (as opposed to genes, which 
define parts inheritance) (Heng et al., 2011a; Heng, 
2009; Heng, 2013). This explanation is often easiest 
to comprehend with the aide of analogy. Imagine that 
each individual gene is a building material - red 
brick, lumber, tile, etc. These are necessary to build 
any kind of building yet, depending on how they are 
arranged, the final results will be drastically different 
- a house, a skyscraper, a laboratory. In this analogy, 
the genome is the blueprint that determines how the 
various materials (genes and their encoded products) 
will come together to ultimately form the complete 
structure (the cell). The three-dimensional 
architecture of the genome therefore governs the 
structure of the genetic and protein networks. Simply 
changing the genomic topology drastically alters the 
relationship among gene interaction, despite similar 
gene content. This has been supported by a recent 
study where karyotypic alterations were shown to 
influence gene expression profiles, and by single cell 
sequencing of glioma (Patel et al., 2014; Stevens et 
al., 2014). In addition, evidence from yeast studies 
strongly supports that aneuploidy directly affects 
gene expression and results in phenotypic variation 
(Pavelka et al., 2010). Genome heterogeneity has 
recently been linked to growth heterogeneity 
(Abdallah et al., 2013), further supporting the 
relationship between karyotype and phenotype. 
Genome-level alteration therefore results in new 
system generation defined by new system 
inheritance. This holds critical importance in tumor 
growth and progression, as karyotypic change can 
potentially result in formation of an aggressive 
phenotype. This would then contribute to further 
tumor progression. Thus from an evolutionary 
standpoint, the importance of stochastic genome 
aberrations in cancer is to increase the evolutionary 
potential of the disease through increased genome 
system heterogeneity, which generates a wide array 
of phenotypes and maximizes the odds of survival 
upon selection. 
In the past, most genetic studies were performed 
using model systems displaying stable genomes (e.g. 
green pea, fly, corn, lab mice). As a result, any 
system inheritance (blueprint) contributions would 
be subtracted (invisible), allowing for illustration of 
a close genotype (mainly the gene level) and 
phenotype relationship. Cancer genetic studies, in 
contrast, are completely different. Cancer evolution 
is driven by genome replacement, making system 
inheritance the most important inheritance while 
making gene-mediated parts inheritance become 
trivial. Interestingly, in cancer, the mechanism(s) 
maintaining various types of inheritance become less 
precise, forming a new type of inheritance, called 
fuzzy inheritance, which provides the mechanism to 
explain the high level of heterogeneity in cancer 
(Heng 2015; Heng et al., 2014; Abdallah et al., 
unpublished observations). 
Without the above understanding, and perhaps also 
due to the overemphasis on gene-based research, 
many key facts about chromosomal aberrations in 
cancer are not well known by most molecular cancer 
researchers. These include the fact that chromosomal 
change is necessary to induce all key transitions 
during cancer evolution, including cellular 
transformation. Even in studies which claim to 
demonstrate the effect of specific genes in 
tumorigenesis, chromosomal alterations are often 
observed in those cells driven to become cancerous 
(Elenbaas et al., 2001; Heng, 2007a; Heng et al., 
2010a; Li et al., 2000). This explains why in cancer 
gene-specific knockout animals, different 
karyotypes and molecular pathways are found to be 
present in different animals' tumors (Bassing et al., 
2003; Heng et al., 2006a; Sharpless et al., 2001). 
Additionally, higher levels of NCCAs have been 
closely linked to more aggressive tumors, solidifying 
the idea that chromosomal change is necessary for 
cancer to evolve and grow (Galipeau et al., 2007; Ye 
et al., 2009;). Tumors with high levels of 
chromosome heterogeneity have also been linked to 
lower patient survival rates, further highlighting the 
clinical importance of this phenomenon (Hicks et al., 
2006; Holland and Cleveland, 2012). 
The concept that only highly penetrant, specific 
genetic alterations are important for cancer 
progression has contributed to the lack of 
appreciation of the importance of stochastic 
chromosomal aberrations as well. The chromosome 
changes mentioned above differ from well-known 
clonal chromosomal aberrations (CCAs), such as the 
Philadelphia chromosome detected in chronic 
myeloid leukemia. These changes do not occur in 
any particular pattern with high frequency, but rather 
they are stochastic, and the prevalence of any 
particular karyotype in a tumor is due to the 
competitive advantage it confers. The seeming 
randomness of karyotypic change in solid tumors fits 
well within the punctuated cancer evolution 
framework. Furthermore, the formation of unique 
genomes in cancer is incredibly common; there is 
proclivity for chromosomal change during every cell 
division when the genome is highly unstable. 
The tradition of ignoring the non-specific changes in 
the cancer research field is the reason that these 
stochastic chromosomal aberrations have only 
recently been reconsidered as drivers of 
tumorigenesis and tumor growth (Castro-Gamero et 
al., 2013; Heng et al., 2004; Heng et al., 2006a; Heng 
et al., 2006b; Heng et al., 2006c; Heng et al., 2010a; 
Klein et al., 2010; McCormack et al., 2013; Podlaha 
et al., 2012; Stepanenko et al., 2013; Stepanenko and 
Kavsan, 2013; Valind and Gisselsson, 2014). The 
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crucial realizations that have led to this 
reconsideration are: chromosome alterations change 
genome-defined systems; the high level of NCCAs 
is essential for cancer evolution (Heng et al., 2006a; 
Heng et al., 2013a); and massive and seemingly 
stochastic chromosomal alterations seem to be the 
only shared findings among many cancer types. 
Knowing the genome variation plays the important 
role in cancer evolution, we should not continue the 
practice of focusing solely on CCAs. 
The somatic cell evolutionary 
pattern  
The two phases of cancer evolution were originally 
based on the karyotype pattern observed in an 
immortalization model where both non-clonal and 
clonal expansions were detected (Heng et al., 
2006a), and have since been confirmed in breast 
cancer using single-cell genome sequencing (Navin 
et al., 2011; Wang et al., 2014).  
Cancer evolution is a series of genome-mediated 
system replacements occurring in dynamic cycles of 
NCCAs and CCAs occurring within the two 
evolutionary phases (Figure 1).  
In the stepwise phase, the majority of cells are clonal 
across generations, and karyotypic diversification is 
traceable.  
The punctuated phase is characterized with a high 
frequency of NCCAs and massive genome 
reorganization, which break multiple system 
constraints (e.g. genome integrity, tissue 
architecture, etc.).  
Thus, cancer progression consists of both macro-
cellular (genome system replacement) and micro-
cellular (modification of the genome-defined 
system) evolution. There is an increased support for 
the concept of macro-micro phases of evolution in 
cancer (Klein, 2013). 
 
Figure 1. Stochastic model of genome-mediated cancer evolution. Cancer evolution is divided into two distinct evolutionary 
phases, the punctuated stochastic phase (or macro-evolutionary phase) and the stepwise gradual phase (or micro-evolutionary 
phase). Punctuated phases are marked by extreme heterogeneity and rapid genome changes, represented by genome system 
changes over time, with each shape representing a unique genome system. Different chromosomes are designated by color 
(red, yellow, blue) and drawn within the nucleus below the corresponding system. Genes are designated A, B, C, D, E, F within 
the chromosomes, and corresponding protein networks are illustrated below by the relationships between proteins A, B, C, D, E, 
F. The punctuated phase is caused by system instability-mediated macro-cellular evolution, resulting in high NCCA frequency 
illustrated by different genome systems (shapes), topologies (karyotypes, including numerical and/or structural chromosome 
aberrations), and protein interactive networks. Following selection pressure, a unique genome system survives (circle). In 
contrast to genomes in the punctuated phase, this genome system in the stepwise phase remains relatively stable over time, 
although it does acquire low-level changes (represented by pie piece changes) such as gene mutations, epigenetic alterations 
and/or small traceable genome-level alterations that aide in adaptation. Genetic/epigenetic alteration is indicated by asterisks (*) 
in the protein network. These micro-cellular changes can be classified into clonal expansion and diversification. Thus, the 
stepwise phase is mainly associated with system stability and micro-cellular evolution. Only one run of the NCCA/CCA cycle is 
presented. 
 
Knowing the two phases of cancer evolution also 
helps in understanding cellular evolutionary 
convergence and divergence of cell populations. In 
addition to distinguishing the evolutionary changes 
that can be traced at genome or gene levels, the 
punctuated phase represents a window where drastic 
divergence frequently occurs. Interestingly, 
phenotype convergence (such as immortalization, 
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metastasis and drug resistance) is often associated 
with karyotype divergence. In contrast, within the 
stepwise phase, genotype and phenotype 
convergence might be observed. 
The evolutionary mechanism of cancer takes into 
account that every factor (genetic, non-genetic, 
internal, external) can contribute to cancer evolution 
as long as it functions as a source of stress to the 
system, particularly when it triggers genome 
instability (Heng et al., 2013a). The evolutionary 
mechanism of cancer is equal to the sum of all 
individual molecular mechanisms (Heng et al., 
2010a) and can be described in three steps: 1) stress-
induced genome system instability; 2) resulting 
heterogeneity at multiple levels (e.g. genomic, 
genetic, epigenetic); and 3) somatic cell evolution. 
The most effective way to drastically increase 
evolutionary potential and drive disease progression 
is through genome-level alteration, which yields new 
genome systems rather than network adjustments 
that may result from gene-level change. The 
evolutionary mechanism of cancer can also be 
explained by multiple level landscape models (Heng 
et al., 2013a; Horne et al., 2014b; Huang, 2013). 
These concepts explain the complexity of cancer, 
including the highly dynamic profiles displayed in 
inter- and intra-tumor samples, the trade-off between 
short-term adaptation and the potential price to pay 
in the long term (Horne et al., 2014a), and the 
unpredictable responses for the majority of 
chemotherapeutic, or even target-specific, drug 
interventions. As mentioned, NCCAs pay a crucial 
role in disease progression by increasing the 
evolutionary potential. Induction of genome chaos 
has been associated with a wide variety of stresses, 
including chemotherapeutics (Liu et al., 2014). Thus, 
as the administration of high-dose 
chemotherapeutics can be initially effective in 
reducing tumor cell numbers, it can also result in the 
generation of new NCCAs, ultimately giving the 
disease a fighting chance for recovery and resistance 
by increasing the evolutionary potential and 
generating aggressive outlier subgroups. 
Individual cell and population 
growth 
This new framework provides new perspective to 
tumor growth at the population and single cell levels. 
Macro- and micro-cellular evolution can now be 
reflected by the dynamic relationship between 
NCCAs and CCAs. This means that cancer 
progression is not only a process of gradual genetic 
tinkering and selection (reflected by CCAs) as once 
thought. Macro-cellular evolution involves drastic 
genome system reorganization, meaning that tumor 
cells can rapidly generate a wide range of growth 
profiles to be selected upon during the punctuated 
phase (reflected by low rates of NCCAs in the stable 
phase and extremely high rates during the 
punctuated phase). This new framework also 
suggests that tumor population growth is a far more 
dynamic process, where aggressive populations can 
emerge and drive growth, but also can be overcome 
by other subgroups further in progression. This is 
very different from traditional thinking, where a 
single, traceable lineage is believed to drive overall 
growth and progression throughout the duration of 
the disease. 
NCCAs provide karyotypic differences, which affect 
many phenotypic traits of cells. In the context of 
tumor growth, the effect of NCCAs on the growth 
rate of cells is especially important. NCCAs and 
CCAs represent survival and growth advantages 
respectively (Ye et al., 2007). Cells grown from 
single clones in populations with unstable 
karyotypes have wildly more variance in growth 
rates when compared with karyotypically stable cell 
lines - and even these 'stable cell lines have more 
variance than would be expected if each daughter 
cell was a perfect copy of its mother (Abdallah et al., 
2013; Kreso et al., 2013). Thus, unstable cancer cells 
produce populations of cells consisting of 
individuals growing at drastically different rates. 
Therefore, the outliers rule in cancer evolution, not 
the average cells in the population. The potential for 
fast-growing outlier cells to drive tumor growth has 
been demonstrated in clonal cells. The population 
doubling time of cells from the same subpopulation 
has been shown to fluctuate, and subpopulations of 
cells with unstable genomes have been observed to 
grow at much higher rates (Abdallah et al., 2013). 
Even a single cell can give rise to heterogeneous 
growth patterns. In essence, heterogeneity is 
heritable - an unstable cell in a population is 
unstable, and thus gives rise to more unstable cells, 
this leads to a hugely diverse population (Kreso et 
al., 2013; Abdallah et al., unpublished observations). 
Fuzzy inheritance aptly explains heterogeneity 
maintenance. Even in comparatively stable cancer 
cell lines, the punctuated phase of evolution and 
phenomena like genome chaos ensure genotypic 
diversity in the population (Abdallah et al., 2013; 
Baca et al., 2013; Liu et al., 2014; Meyerson and 
Pellman, 2011). 
The framework also reveals the impact and power of 
the single cell in tumor growth.  
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Recently, single-cell and population based 
experiments have shown that, within a 
heterogeneous population, aggressive outliers 
influence the growth of the entire population through 
rapid increase of cell numbers (Abdallah et al., 
2013). Taking macro-cellular evolution into 
consideration, aggressive outlier cells are rapidly 
generated and drive tumor growth. Thus, the 
population dynamics of the tumor are influenced by 
rapid formation and transient contributions of outlier 
groups. However, current average-based 
technologies do not account for these outliers, as 
these data are washed away in these types of 
analyses. In fact for unstable cell populations, the 
average is irrelevant, as it does not exist within the 
population (Abdallah et al., 2013)! As a result of 
averaging, the true contribution of outlier subgroups 
is lost, and our understanding of tumor growth is 
skewed. In order to appropriately gauge the patient's 
disease status (genome heterogeneity and stability), 
application of single-cell based techniques (e.g. 
spectral karyotyping, single-cell sequencing) is 
essential before and during treatment regimens. 
Future perspective 
The above analyses illustrate the ultimate 
importance of cytogenetic and cytogenomic 
approaches in cancer research, especially for 
studying cell population behavior and the pattern of 
macro-cellular evolution. In the future, monitoring 
karyotype change will be essential for gene-based 
cancer research, as karyotype alteration likely results 
in the formation of new molecular network 
structures, which also change the gene context. In 
addition, as cancer is a highly dynamic evolutionary 
process, and no simple constant clonal expansion 
pattern driven by gene mutation accumulation is 
shared across all studies (especially in drug 
resistance studies), cytogenetic monitoring must be 
applied to define the context. Furthermore, 
cytogenetic approaches can provide low cost 
individual cell and cell population profiling. 
In order to better understand the dynamic growth of 
cancer cells and the evolutionary pattern, we call for 
a shift from continuing collecting lower level 
molecular data that offer little clinical value towards 
monitoring the system behavior of cancer in an 
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evolutionary, holistic context. Achieving this 
requires focus at the genome level, and importantly, 
inclusion of NCCAs in analyses. This includes both 
understanding the various types of chromosomal 
aberrations (Table 1) as well as incorporating NCCA 
frequencies in measurements of genome instability. 
First, there are still many unclassified and/or yet to 
be generally accepted chromosomal aberrations 
frequently observed from cytogenetic preparations 
of cancer materials that need to be characterized or 
scored (Heng et al., 1988a; Heng et al., 2004; Heng 
et al., 2013). According to our analyses, these 
chromosomal aberrations represent evolutionary 
potential and provide reliable biomarkers of the 
entire tumor cell population. 
Second, despite the importance of chromosomal 
instability (CIN) studies in cancer, traditional 
cytogenetic analysis has focused on CCAs, and 
NCCAs have been dismissed as insignificant genetic 
"noise". To change this situation, it is necessary to 
use frequencies of NCCAs rather than CCAs to 
measure CIN, and to study and classify diverse types 
of NCCAs and compare the relationships among 
these chromosomal aberrations. NCCAs provide 
diversity to the population, as a population 
consisting of many NCCAs is more robust, and thus 
has a greater amount of evolutionary potential (Heng 
et al., 2013a; Liu et al., 2014). The fact that NCCAs 
are so common suggests that such a potential is 
required for most cancer populations to survive and 
grow. The status of NCCAs can also be used to 
differentiate tumor types, distinguish cancer stages, 
and predict treatment response (Duesberg et al., 
2007; Heng 2007a; Heng et al., 2010b; Ye et al., 
2009). 
Accounting for tumor cell growth heterogeneity is 
also crucial, given recent findings regarding the 
impact of outlier influence in cancer population 
growth. Like cancer genome analyses, cancer growth 
analyses require a shift away from averaging 
methods, as these wash away outlier contributions 
and provide a misrepresentation of the population 
(Abdallah et al., 2013). In addition, further work is 
needed in understanding the growth pattern 
differences between NCCAs and CCAs. The 
heterogeneous growth (and death) of tumor cells 
means that many cancer cells will die during 
progression (Stevens et al., 2013), but the overall 
tumor population marches on, and this 
understanding has relevance in treatment regimens 
and drug resistance. Thus, cytogenetic analysis has 
the capability to identify and offer prediction power 
of outliers within unstable cell populations, which 
can drive the direction of somatic cellular evolution, 
and this drastically differs from stable cell 
populations where the "average profile" rules. 
Considering the roles of massive genome 
reorganization (i.e. genome chaos), resultant 
NCCAs, and aggressive outliers in tumor growth, 
current therapeutic approaches involving the 
administration of maximum tolerated doses must be 
reconsidered. High dose treatment can significantly 
reduce tumor cell populations initially. However, 
since varying sources of stress have been previously 
associated with genome chaos, rapid genome 
reorganization can be induced, potentially resulting 
in the generation of aggressive outlier groups. This 
would then result in the rapid repopulation of the 
tumor cell population and further drive disease 
progression and drug resistance. This mechanism 
can explain some early, promising successes in 
alternative approaches including adaptive and 
metronomic therapies. The aim of adaptive therapy 
is to maintain a stable tumor burden rather than 
elimination, and this is achieved by therapeutic dose 
adjustments (Gatenby et al., 2009; Silva et al., 2012). 
Metronomic therapy aims to eliminate tumors, 
however, this differs from the maximum tolerated 
dose strategy as lower drug concentrations are 
administered in a rhythmic regimen (Kerbel and 
Kamen, 2004). These approaches both utilize lower 
doses of chemotherapeutics, which may not induce 
genome chaos and macro-cellular evolution. Perhaps 
the key to successfully constraining tumor cell 
growth and improving patient outcome is through 
applying genome constraint with milder dosage. In 
addition, considering that genes are considered 
moving targets in genome-mediated evolution and 
various stresses can induce chromosomal instability 
and genome chaos, emphasis should be placed on 
determining the appropriate degree of stress when 
designing regimens rather than the specific target(s). 
We recently studied the transition cells undergo after 
treatment. Initially, high cell death is induced. 
However, cells in culture models recover over time. 
We have found that harsh initial treatments result in 
the production of outliers that can outgrow untreated 
cell populations after recovery (Horne et al., 
unpublished observations). 
Focusing on the overall heterogeneity of the cell 
population, as reflected by the NCCA frequency and 
outlier profiles (e.g. chaotic genome complexity), 
will result in an improved understanding of cancer 
progression and provide accurate prediction 
measures. Experimental efforts are urgently needed 
in order to translate these concepts to clinical 
application. Clearly, more attention is needed on 
genome level alteration and genome mediated 
somatic cell evolution, which play important roles in 
understanding and predicting the behavior of cell 
populations and how they grow (Abdallah et al., 
2013; Heng et al., 2006a; Horne and Heng, 2014; Ye 
et al., 2007). 
 
Finally, observing the dynamics of tumor cell growth 
(both in vivo and in vitro) has provided a unique 
opportunity to watch somatic cell evolution in 
action. Since both macro- and micro-cellular 
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evolution can be observed, tumor cell growth 
represents a great model to study how the different 
types of inheritance including gene-mediated parts 
inheritance, genome-mediated system inheritance, 
and tissue-specific fuzzy inheritance impact on 
evolutionary dynamics. Understanding the pattern of 
tumor cell evolution will lead to new strategies for 
managing cancer. 
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